Bacteriophage Therapy: Clinical Trials and Regulatory Hurdles.
TLDR
This review discusses the multi-drug resistant Gram-negative pathogens of highest critical priority and summarizes the current state-of-the-art in phage therapy targeting these organisms.Abstract:
Increasing reports of antimicrobial resistance and limited new antibiotic discoveries and development have fuelled innovation in other research fields and led to a revitalization of bacteriophage (phage) studies in the Western world. Phage therapy mainly utilizes obligately lytic phages to kill their respective bacterial hosts, while leaving human cells intact and reducing the broader impact on commensal bacteria that often results from antibiotic use. Phage therapy is rapidly evolving and has resulted in cases of life-saving therapeutic use and multiple clinical trials. However, one of the biggest challenges this antibiotic alternative faces relates to regulations and policy surrounding clinical use and implementation beyond compassionate cases. This review discusses the multi-drug resistant Gram-negative pathogens of highest critical priority and summarizes the current state-of-the-art in phage therapy targeting these organisms. It also examines phage therapy in humans in general and the approaches different countries have taken to introduce it into clinical practice and policy. We aim to highlight the rapidly advancing field of phage therapy and the challenges that lie ahead as the world shifts away from complete reliance on antibiotics.read more
Citations
More filters
Journal ArticleDOI
Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review.
TL;DR: This review provides a comprehensive overview of factors that determinephage circulation, penetration, and clearance, and that in consequence determine phage applicability for medicine.
Journal ArticleDOI
Bacteriophages as Alternatives to Antibiotics in Clinical Care.
TL;DR: This review reports on the applications of phage therapy for various infectious diseases, phage pharmacology, immunological responses to phages, legal concerns, and the potential benefits and disadvantages of this novel treatment.
Journal ArticleDOI
Current challenges and future opportunities of phage therapy
TL;DR: This review scour the outcomes of human phage therapy clinical trials and case reports and address the major barriers that stand in the way of using phages in clinical settings, particularly the potential of phage resistance to hinder phage Therapy.
Journal ArticleDOI
Phage Therapy for Limb-threatening Prosthetic Knee Klebsiella pneumoniae Infection: Case Report and In Vitro Characterization of Anti-biofilm Activity
Edison J Cano,Katherine M. Caflisch,Paul L. Bollyky,Jonas D. Van Belleghem,Robin Patel,Joseph Fackler,Michael J Brownstein,Bri'Anna Horne,Biswajit Biswas,Matthew Henry,Francisco Malagon,David G. Lewallen,Gina A. Suh +12 more
TL;DR: The addition of phage was associated with a satisfactory outcome in this case of intractable biofilm-associated prosthetic knee infection and holds promise for treatment of device-associated infections.
Journal ArticleDOI
The Preclinical and Clinical Progress of Bacteriophages and Their Lytic Enzymes: The Parts are Easier than the Whole.
Karim Abdelkader Soufi Abdelkader,Hans Gerstmans,Hans Gerstmans,Amal E. Saafan,Tarek Dishisha,Yves Briers +5 more
TL;DR: The therapeutic potential of phages has been considered since their first identification more than a century ago as mentioned in this paper, however, the most provocative and unique properties of phage such as high specificity, self-replication and co-evolution prohibited a rapid preclinical and clinical development.
References
More filters
Journal ArticleDOI
Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.
Evelina Tacconelli,Elena Carrara,Alessia Savoldi,Stéphan Juergen Harbarth,Marc Mendelson,Dominique L Monnet,Céline Pulcini,Gunnar Kahlmeter,Jan Kluytmans,Yehuda Carmeli,Marc Ouellette,Kevin Outterson,Jean B. Patel,Marco Cavaleri,Edward Cox,Christopher R. Houchens,M Lindsay Grayson,Paul Hansen,Nalini Singh,Ursula Theuretzbacher,Nicola Magrini,Aaron O. Aboderin,Seif Al-Abri,Nordiah Awang Jalil,Nur Benzonana,Sanjay Bhattacharya,Adrian Brink,Francesco Robert Burkert,Otto Cars,Giuseppe Cornaglia,Oliver J. Dyar,Alexander W. Friedrich,Ana Cristina Gales,Sumanth Gandra,Christian G. Giske,Debra A. Goff,Herman Goossens,Thomas Gottlieb,Manuel Guzman Blanco,Waleria Hryniewicz,Deepthi Kattula,Timothy Jinks,Souha S. Kanj,Lawrence Kerr,Marie-Paule Kieny,Yang Soo Kim,Roman S. Kozlov,Jaime Labarca,Ramanan Laxminarayan,Karin Leder,Leonard Leibovici,Gabriel Levy-Hara,Jasper Littman,Surbhi Malhotra-Kumar,Vikas Manchanda,Lorenzo Moja,Babacar Ndoye,Angelo Pan,David L. Paterson,Mical Paul,Haibo Qiu,Pilar Ramon-Pardo,Jesús Rodríguez-Baño,Maurizio Sanguinetti,Sharmila Sengupta,Mike Sharland,Massinissa Si-Mehand,Lynn L. Silver,Wonkeung Song,Martin Steinbakk,Jens Thomsen,Guy E. Thwaites,Jos W. M. van der Meer,Nguyen Van Kinh,Silvio Vega,Maria Virginia Villegas,Agnes Wechsler-Fördös,Heiman F. L. Wertheim,Evelyn Wesangula,Neil Woodford,Fidan O Yilmaz,Anna Zorzet +81 more
TL;DR: Future development strategies should focus on antibiotics that are active against multidrug-resistant tuberculosis and Gram-negative bacteria, and include antibiotic-resistant bacteria responsible for community-acquired infections.
Journal ArticleDOI
Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist.
TL;DR: Pseudomonas aeruginosa is an ubiquitous pathogen capable of infecting virtually all tissues as discussed by the authors, and a large variety of virulence factors contribute to its importance in burn wounds, lung infection and eye infection.
Journal ArticleDOI
Pseudomonas aeruginosa: all roads lead to resistance.
TL;DR: Very large collections of genes (the resistome) that when mutated lead to resistance as well as new forms of adaptive resistance that can be triggered by antibiotics themselves, in in vivo growth conditions or complex adaptations such as biofilm growth or swarming motility are identified.
Journal ArticleDOI
Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050
TL;DR: Marlieke de Kraker and colleagues reflect on the need for better global estimates for the burden of antimicrobial resistance and suggest that more needs to be done to estimate this burden.
Journal ArticleDOI
A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy.
TL;DR: A therapeutic bacteriophage preparation targeting antibiotic‐resistant Pseudomonas aeruginosa in chronic otitis is evaluated to evaluate the efficacy and safety of this preparation.
Related Papers (5)
A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy.
Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection
Robert T. Schooley,Biswajit Biswas,Jason J. Gill,Adriana Hernandez-Morales,Jacob C. Lancaster,Lauren Lessor,Jeremy J. Barr,Jeremy J. Barr,Sharon L. Reed,Forest Rohwer,Sean Benler,Anca M. Segall,Randy Taplitz,Davey M. Smith,Kim M. Kerr,Monika Kumaraswamy,Victor Nizet,Victor Nizet,Leo Lin,Melanie McCauley,Steffanie A. Strathdee,Constance A. Benson,Robert K. Pope,Brian M. Leroux,Andrew C. Picel,Alfred J. Mateczun,Katherine E. Cilwa,James Regeimbal,Luis A. Estrella,David M. Wolfe,Matthew Henry,Javier Quinones,Scott Salka,Kimberly A. Bishop-Lilly,Ry Young,Theron Hamilton +35 more